In vivo (Athens, Greece) · 2026
Successful Management of Ultra-high-risk Mixed Ovarian Germ Cell Tumor Using a Pediatric-inspired Intensive Chemotherapy Regimen: A Case Report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Juhun, Lee Hyun Jung, Song Seung Ho, Park Seo Young, Kim Dong Ja, Lee In Hee, Park Meerim, Lim Myong Cheol, Park Sang-Yoon, Kim Ji Hyun
Аннотация
BACKGROUND/AIM: Non-gestational ovarian choriocarcinoma is an extremely aggressive malignancy with limited standardized treatment protocols. We present a successful multidisciplinary approach for a high-risk mixed malignant ovarian germ cell tumor (MOGCT) containing a predominant choriocarcinomatous component.
CASE REPORT: A 33-year-old woman presented with acute hemoperitoneum. Pathology confirmed a mixed MOGCT (60% dysgerminoma, 40% choriocarcinoma, focal yolk sac tumor), International Federation of Obstetrics and Gynecology stage IVB. Following optimal cytoreductive surgery, a multidisciplinary tumor board, incorporating pediatric oncology paradigms, initiated a dose-dense, modified regimen of cyclophosphamide, bleomycin, etoposide, cisplatin, and methotrexate (Cy-BEP-MTX), administered every 2 weeks. This intensified strategy aimed to suppress rapid tumor repopulation. The patient tolerated seven cycles of this therapy and achieved complete remission, currently maintaining progression-free survival for 3 years.
CONCLUSION: For ultra-high-risk non-gestational ovarian choriocarcinoma, optimal surgery followed by a pediatric-inspired, dose-dense chemotherapy regimen may provide a superior curative chance compared to standard protocols for adults, highlighting the value of interdisciplinary collaboration.
CASE REPORT: A 33-year-old woman presented with acute hemoperitoneum. Pathology confirmed a mixed MOGCT (60% dysgerminoma, 40% choriocarcinoma, focal yolk sac tumor), International Federation of Obstetrics and Gynecology stage IVB. Following optimal cytoreductive surgery, a multidisciplinary tumor board, incorporating pediatric oncology paradigms, initiated a dose-dense, modified regimen of cyclophosphamide, bleomycin, etoposide, cisplatin, and methotrexate (Cy-BEP-MTX), administered every 2 weeks. This intensified strategy aimed to suppress rapid tumor repopulation. The patient tolerated seven cycles of this therapy and achieved complete remission, currently maintaining progression-free survival for 3 years.
CONCLUSION: For ultra-high-risk non-gestational ovarian choriocarcinoma, optimal surgery followed by a pediatric-inspired, dose-dense chemotherapy regimen may provide a superior curative chance compared to standard protocols for adults, highlighting the value of interdisciplinary collaboration.